However, in acute myeloid leukemia (AML) patients with activating mutations in FMS‐like tyrosine kinase 3 (FLT3), USP10 deubiquitinates and stabilizes FLT3 by removing the proteolytic polyubiquitin chains and preventing FLT3 degradation, to aggravate tumor progress (Weisberg et al., 2017). The gene discussed is USP10; the disease is acute myeloid leukemia.